Key facts
- Atmen Pharmaceutical’s last known valuation is $225.4M (Sep 2024).
- It has raised $14.5M; the latest was Early Stage VC in Jan 2025.
- Notable investors include Hunan Chasing Fund, Soochow Venture Capital, WinDigital Capital Management.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Atmen Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Atmen Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atmen Pharmaceutical
Developer of drug-device combination platform drugs to better serve patients. The company is committed to researching, developing, and producing drug-device combination platform drugs, including inhalation powder aerosols and inhalation sprays.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Website
- atmenpt.com/
- Ownership
- Privately Held (backing)
Atmen Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atmen Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atmen Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.